Buy Nifuroxazide

constitutive activation of STAT3 transcription factor contributes to the pathogenesis of many cancers, including multiple myeloma (MM). Since STAT3 is unnecessary in most normal tissues, inhibition of STAT3 target for patients with these cancers, an attractive therapy. To identify STAT3 inhibitors, we have developed a test based transcriptional and screened a library of compounds are known to be safe in humans. We found the drug nifuroxazide a potent inhibitor of STAT3 function. Nifuroxazide inhibits the constitutive phosphorylation of STAT3 in MM cells Jak kinase autophosphorylation reduced and results in a down regulation of the target gene STAT3 Mcl-1. Nifuroxazide caused a decrease in the viability of primary myeloma cells and cell lines of STAT3 activation myeloma includes, but not normal peripheral mononuclear blood cells. Although bone cell survival signals provide stromal marrow to myeloma cells may nifuroxazide to remedy this survival advantage. According to the interaction of STAT3 with other cellular pathways, shows increased cytotoxicity nifuroxazide combined if either the histone deacetylase inhibitor depsipeptide or MEK inhibitor UO 126. Therefore, a mechanistic screen based we have found clinically relevant drugs nifuroxazide a potent inhibitor STAT signaling, cytotoxicity against myeloma cells shows that depend for their survival on STAT3.